Hsbc Holdings PLC Has $290,000 Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)

Hsbc Holdings PLC lessened its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 32.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,967 shares of the company’s stock after selling 13,678 shares during the period. Hsbc Holdings PLC’s holdings in Kodiak Sciences were worth $290,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the company. PNC Financial Services Group Inc. lifted its stake in shares of Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock valued at $32,000 after purchasing an additional 2,988 shares during the period. US Bancorp DE bought a new stake in Kodiak Sciences in the fourth quarter worth approximately $40,000. Headlands Technologies LLC bought a new position in shares of Kodiak Sciences during the 4th quarter worth approximately $90,000. JPMorgan Chase & Co. boosted its holdings in shares of Kodiak Sciences by 220.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock worth $117,000 after buying an additional 30,735 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Kodiak Sciences during the 4th quarter worth approximately $118,000. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Stock Performance

Shares of NASDAQ:KOD opened at $3.77 on Friday. Kodiak Sciences Inc. has a 52-week low of $1.92 and a 52-week high of $11.60. The business’s 50 day simple moving average is $3.28 and its two-hundred day simple moving average is $5.48. The firm has a market cap of $198.88 million, a P/E ratio of -1.03 and a beta of 2.42.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.06. On average, equities analysts forecast that Kodiak Sciences Inc. will post -3.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating and set a $3.00 target price on shares of Kodiak Sciences in a research note on Monday, March 31st.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.